Is LIMN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LIMN. It does not provide personalized investment advice.

LIMN (Liminatus Pharma, Inc. Class A Common Stock) Stock Analysis - Financials

Liminatus Pharma, Inc. Class A Common Stock (LIMN) is a publicly traded Healthcare sector company. As of September 10, 2026, LIMN trades at $3.60 with a market cap of $4.86M and a P/E ratio of -8.35. LIMN moved +0.00% today. Year to date, LIMN is -88.59%; over the trailing twelve months it is -97.16%. Its 52-week range spans $3.42 to $1,683.00. Rallies surfaces LIMN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are LIMN's key financials?

LIMN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LIMN recently traded at $3.60. Market cap is $4.86M. P/E ratio is -8.35. Revenue is $0.

LIMN Key Metrics

Key financial metrics for LIMN
Metric	Value
Price	$3.60
Market Cap	$4.86M
P/E Ratio	-8.35
EPS	$-0.43
Dividend Yield	0.00%
52-Week High	$1,683.00
52-Week Low	$3.42
Volume	3.35K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-10.21M
Gross Margin	0.00%

LIMN Analyst Consensus

LIMN analyst coverage data. Average price target: $0.00.

Common questions about LIMN

What are LIMN's key financials?: LIMN financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. LIMN recently traded at $3.60. Market cap is $4.86M. P/E ratio is -8.35. Revenue is $0.
Is LIMN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LIMN. It does not provide personalized investment advice.